Table 1 |
||
|
Patient details and antibody frequencies |
||
| n (%) |
||
|
|
||
| Polymyositis |
Dermatomyositis |
|
|
|
||
| (n = 117) |
(n = 108) |
|
|
|
||
| Females |
81 (69.2) |
75 (69.4) |
| Average age of onseta |
50.4 ± 14.5 |
49.0 ± 14.1 |
| Interstitial lung disease |
18 (15.4) |
19 (17.6) |
| Malignancyb |
2 (1.7) |
14 (13.0) |
| Antibody status |
(n = 105) |
(n = 101) |
| Myositis-specific antibodies |
||
| Jo-1 |
24 (22.9) |
22 (21.8) |
| PL-7 |
1 (1.0) |
0 |
| PL-12 |
0 |
1 (1.0) |
| EJ |
0 |
1 (1.0) |
| OJ |
1 (1.0) |
1 (1.0) |
| KS |
1 (1.0) |
1 (1.0) |
| Any of the abovec |
27 (25.7) |
25 (24.7) |
| Mi-2d |
1 (1.0) |
17 (16.8) |
| SRP |
5 (4.8) |
2 (2.0) |
| Myositis-associated antibodies |
||
| U1-RNP |
5 (4.8) |
8 (7.9) |
| U3-RNP |
0 |
2 (2.0) |
| Ku |
0 |
2 (2.0) |
| PM-Scl |
5 (4.8) |
6 (5.9) |
| None of the above autoantibodies |
62 (59.1) |
45 (44.5) |
|
|
||
|
aResults expressed as mean ± standard deviation. bDermatomyositis (DM) versus polymyositis (PM), p = 0.001; odds ratio (OR) 8.6, (95% confidence interval (CI) 1.9–78.9). cThe total for DM is 25 despite the presence of 26 anti-tRNA synthetases, due to one patient possessing both anti-Jo-1 and anti-PL-12. dDM versus PM, p = 2.9 × 10-5; OR 21.0 (95% CI 3.1–887.7). |
||
|
Chinoy et al. Arthritis Research & Therapy 2006 8:R13 doi:10.1186/ar1862 |
||
